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Molecular chaperones, especially members of
the heat shock protein 90 (Hsp90) family, are
thought to promote tumor cell survival, but this
function is not well understood. Here, we show
that mitochondria of tumor cells, but not most
normal tissues,containHsp90and its relatedmol-
ecule, TRAP-1. These chaperones interact with
CyclophilinD, an immunophilin that inducesmito-
chondrial cell death, and antagonize its function
via protein folding/refolding mechanisms. Dis-
abling this pathway using novel Hsp90 ATPase
antagonists directed to mitochondria causes
sudden collapse of mitochondrial function and
selective tumor cell death. Therefore, Hsp90-
directed chaperones are regulators of mitochon-
drial integrity, and their organelle-specific antag-
onists may provide a previously undescribed
class of potent anticancer agents.
INTRODUCTION
Heat shock protein 90 (Hsp90) is an essential ATPase-di-
rected molecular chaperone (Young et al., 2004) that as-
sists in protein folding quality control (Young et al., 2001),
maturation of client proteins (Pearl and Prodromou, 2006),
and protein trafficking among specialized subcellular com-
partments (Young et al., 2003). Because of its restricted
repertoire of client proteins, typically kinases and signaling
molecules, Hsp90 occupies a unique nodal role in cellular
homeostasis, overseeing cell proliferation and cell-survival
mechanisms (Pearl and Prodromou, 2006). These proper-
ties are commonly exploited in cancer where Hsp90 is not
onlyupregulated (Isaacset al., 2003), but itsATPaseactivity
is also increased by approximately 100-fold, as compared
to that of normal tissues (Kamal et al., 2003).
In tumor cells, Hsp90 is thought to orchestrate a broad
cell-survival program (Isaacs et al., 2003; Whitesell and
Lindquist, 2005), which has been linked to stabilizationof cell viability effectors (Sato et al., 2000), adaptation to
unfavorable environments (Beere, 2004), and inhibition
of mitochondria-initiated apoptosis (Pandey et al., 2000).
Because of its multiple roles as a cancer gene, and the po-
tential ‘‘drugability’’ of its ATPase pocket, Hsp90 has been
pursued for novel cancer therapeutics (Isaacs et al., 2003),
and a small molecule Hsp90 antagonist derived from
geldanamycin (GA), i.e., 17-allylamino-demethoxygelda-
namycin (17-AAG) (Neckers and Ivy, 2003), has entered
clinical testing in cancer patients (Collins and Workman,
2006). However, the response to this agent proved difficult
to interpret. This reflected a modest anticancer activity
(Drysdale et al., 2006) that was inconsistent with a pre-
dicted essential role of Hsp90 in tumor maintenance
(Neckers and Ivy, 2003), paradoxical activation of onco-
genic kinases (Koga et al., 2006), induction of antiapop-
totic mechanisms (Beere, 2004), and increasedmetastatic
dissemination (Price et al., 2005). It is therefore clear
that Hsp90 homeostasis in tumors involves cell-survival
mechanisms that escape inhibition by current ATPase an-
tagonists, and unraveling these pathways has become a
priority to identify more effective anticancer agents.
Mitochondria play a critical role in cell survival and cell
death (Green and Kroemer, 2004). Dysfunction and loss
of integrity of these organelles are molecular prerequisites
of multiple cell death pathways, characterized by in-
creased permeability of the inner mitochondrial mem-
brane, loss of membrane potential, swelling of the matrix,
and ultimately rupture of the outer membrane with release
of apoptogenic proteins, i.e., cytochrome c, in the cytosol
(Green and Kroemer, 2004). How this process of
‘‘mitochondrial permeability transition’’ is regulated is
not completely understood (Green and Kroemer, 2004),
as components of a ‘‘permeability transition pore,’’ includ-
ing the voltage-dependent anion channel (VDAC-1), the
adenine nucleotide translocator (ANT), or the immunophi-
lin Cyclophilin D (CypD), were found to be either dispens-
able (Kokoszka et al., 2004; Krauskopf et al., 2006), or
implicated in some, but not all, forms of mitochondrial
cell death (Baines et al., 2005; Nakagawa et al., 2005).
Although therapeutic manipulation of mitochondrial per-
meability transition may hold promise for novel cancerCell 131, 257–270, October 19, 2007 ª2007 Elsevier Inc. 257
therapeutics (Johnstone et al., 2002), it is unclear whether
mitochondrial homeostasis is differentially regulated in tu-
mor versus normal cells to make this approach safe and
devoid of side effects.
In this study, we investigated mechanisms of Hsp90
cytoprotection in tumors. We found that mitochondria of
tumor cells, but not most normal tissues, organize a chap-
erone network comprising Hsp90, its related molecule,
TRAP-1 (Felts et al., 2000), and CypD, which antagonizes
mitochondrial permeability transition. Organelle-specific
targeting of this pathway causes sudden collapse of
mitochondrial integrity and apoptosis selectively in tumor
cells.
RESULTS
Hsp90 Chaperones in Mitochondria
Webegan this study by askingwhether Hsp90 contributed
to mitochondrial cell death pathways, especially in tu-
mors. An Hsp90-related molecule known as TRAP-1 that
binds ATPase pocket antagonists has been reported in
mitochondria (Cechetto and Gupta, 2000; Felts et al.,
2000). Consistent with this, an antibody to TRAP-1 de-
tected an abundant 75 kDa immunoreactive band in pu-
rified mitochondria from various tumor cells (Figure 1A,
top). Conversely, TRAP-1 was expressed at very low
levels in mitochondria isolated from normal mouse tissues
(Figure 1A, bottom) and was absent in the cytosol of tumor
or normal cells (Figure 1A and data not shown) (Chen et al.,
1996).We next looked at TRAP-1 expression in primary tu-
mor specimens and their matched normal tissues in vivo.
By immunohistochemistry, TRAP-1 was intensely ex-
pressed in tumor cells of adenocarcinoma of the pancreas
(Figure 1C), breast (Figure 1E), colon (Figure 1G), and lung
(Figure 1I). Conversely, normal matched epithelia con-
tained very low levels of TRAP-1 (Figures 1B, 1D, 1F, and
1H), and IgG did not stain normal or tumor tissues (data
not shown).
Next, we asked whether Hsp90 was also expressed in
mitochondria. In addition to cytosol, an abundant pool of
Hsp90 was detected by western blotting in mitochondria
of various tumor cells (Figure 1J). Accordingly, an antibody
to Hsp90 labeled purified tumor mitochondria (26.6 ± 4.1
gold particles/mitochondria, n = 13) by electron micros-
copy (Figure 1K), whereas IgG was unreactive (1.1 ±
0.33 gold particles/mitochondria, n = 13; p < 0.0001)
(Figure 1L). To confirm this localization of Hsp90 chaper-
ones, we next checked the purity of our mitochondrial
preparations. Mitochondria isolated from HeLa cells con-
tained TRAP-1 and Hsp90 but not proteins of the endo-
plasmic reticulum (calnexin) or cytosol (GAPDH) and
very low amounts of Lamp-1, a lysosomal marker (Fig-
ure 1M). Then, we tested whether Hsp90 was actively im-
ported in mitochondria. 35S-labeled Hsp90 accumulated
inside isolated brain mitochondria, and this reaction was
abolished by the uncoupler, valinomycin (Figure 2A). Sim-
ilar results were obtained with 35S-PiC, a mitochondrial258 Cell 131, 257–270, October 19, 2007 ª2007 Elsevier Inc.phosphate carrier used as a control for the import reaction
(Figure 2A).
To map the submitochondrial localization of Hsp90, we
first degraded the outer membrane proteins, including
Bcl-2, with proteinase K (PK). This did not reduce Hsp90
reactivity in mitochondria (Figure S1), suggesting that it
was protected from proteolysis. Conversely, permeabili-
zation of the outer membrane with digitonin released
Hsp90 from mitochondrial pellets into the supernatant,
whereas matrix-associated mt-Hsp70 was unaffected
(Figure 2B). Next, we mechanically disrupted the outer
membrane in the absence of sucrose, which completely
depleted Smac from the intermembrane space, without
affecting CypD in the matrix (Figure 2C). Under these con-
ditions, Hsp90 levels were only partially reduced
(Figure 2C), suggesting altogether that it localized to
both the matrix and the mitochondrial intermembrane
space. To validate this, we next used a submitochondrial
fractionation protocol that allows the isolation of the outer
membrane (OM), the intermembrane space (IMS), the in-
ner membrane (IM), and the matrix (MA). Consistent with
the digitonin/proteinase K mapping data (Figures 2B and
2C), Hsp90was present in both the IMS and themitochon-
drial matrix (Figure 2D).
Similar to TRAP-1, mitochondrial Hsp90 was not ex-
pressed in normal mouse tissues, except for brain and
testis (Figures S1 and 2E). Conversely, cytosolic Hsp90
was ubiquitous in normal and tumor cells (Figure 2E). Anal-
ysis of human cells gave comparable results, with Hsp90
and TRAP-1 abundantly present in tumor cells but ex-
pressed at low levels in three normal fibroblast cell types
(Figure 2F). This was not due to a global reduction in chap-
erone levels because only the mitochondrial pools of
Hsp90 and TRAP-1were reduced in normal cells, whereas
cytosolic Hsp90 was comparably expressed in normal or
tumor cells (Figure 2G).
Mitochondrial Hsp90 Chaperones Regulate
Permeability Transition
To probe the function of Hsp90 chaperones in mitochon-
dria, we used two ATPase pocket antagonists currently
explored as anticancer agents, the small molecule GA de-
rivative, 17-AAG (Isaacs et al., 2003), and the peptidomi-
metic Shepherdin, which contains an Antennapedia helix
III homeodomain cell-penetrating sequence (Plescia
et al., 2005). Fluorescein-conjugated Shepherdin accu-
mulated inside purified tumor mitochondria (Figure 3A),
whereas no fluorescence was detected for Shepherdin
lacking the Antennapedia sequence (Figure 3B), or in the
absence of mitochondria (Figure 3C). A fluorescein-conju-
gated cell-permeable scrambled peptidomimetic also
accumulated in isolated mitochondria (Figure 3D), quanti-
tatively indistinguishably from Shepherdin (Figure 3E).
Analysis of submitochondrial compartments revealed
that Shepherdin accumulated in the IMS, the IM, and the
MA (Figure 3F). This localization was entirely dependent
on the Antennapedia peptide because Shepherdin lacking
this sequence was not found in mitochondria (Figure 3F).
Figure 1. Mitochondrial Hsp90 Chaperones
(A) Differential mitochondrial localization of TRAP-1. Cytosolic or mitochondrial extracts of tumor cells (top) or mitochondria from normal mouse
organs (bottom) were analyzed by western blotting.
(B–I) In vivo expression. Tissue specimens of normal pancreas (B), breast (D), colon (F), or lung (H) or cases of adenocarcinoma of pancreas (C), breast
(E), colon (G), or lung (I) were stained by immunohistochemistry with an antibody to TRAP-1. Magnification 3400.
(J) Mitochondrial Hsp90 in tumor cells. The indicated tumor cell lines were fractionated in mitochondria or cytosolic extracts and analyzed by western
blotting.
(K and L) Electron microscopy. HeLa cell mitochondria were labeled with an antibody to the N domain of Hsp90 (K) or IgG (L), stained with gold-
conjugated secondary reagent, and analyzed by electron microscopy. Magnification 352,000; 328,000.
(M) Purity of isolated subcellular fractions. Total cytosol extracts (TCE), isolated mitochondria (PK-treated), or cytosolic extracts from HeLa cells were
analyzed by western blotting.Next, we askedwhether Shepherdin directly boundHsp90
molecules in mitochondria in vivo. Fractionation of Raji
mitochondrial extracts over Shepherdin-Sepharose re-
sulted in the specific elution of both TRAP-1 and Hsp90
(Figure 3G, top), whereas no bands were affinity-purifiedby the scrambled peptidomimetic coupled to Sepharose
(Figure 3G, bottom).
When tested on isolated tumor mitochondria, Shepher-
din induced sudden loss of mitochondrial membrane po-
tential, in a reaction progressively titrated out at increasingCell 131, 257–270, October 19, 2007 ª2007 Elsevier Inc. 259
Figure 2. Characterization of Mitochondrial Hsp90
(A) Mitochondrial import. Purified mitochondria were incubated with 35S-Hsp90 or 35S-PiC with (+) or without () valinomycin and analyzed by
autoradiography.
(B) Digitonin treatment. PK-treated HeLa cell mitochondria were incubatedwith digitonin, and pellets (P) or supernatants (S) were analyzed bywestern
blotting.
(C) Outer membrane disruption. HeLa cell mitochondria were suspended in buffer with (SHE) or without (HE) sucrose in the presence or absence of PK
and analyzed by western blotting.
(D) Submitochondrial fractionation. HeLa cell mitochondrial extracts (MTE) were fractionated in outer membrane (OM), intermembrane space (IMS),
inner membrane (IM), and matrix (MA) and analyzed by western blotting.
(E) Differential Hsp90 expression in normal tissues. Mouse organs fractionated in mitochondria (left) or cytosol (right) were analyzed by western
blotting.
(F) Comparative analysis of normal versus tumor cell types. Total cell extracts from tumor (HeLa, MCF-7, Raji) or normal (HFF, HGF, WS-1) cells were
analyzed by western blotting.
(G) Subcellular fractionations. The indicated normal cell types or HeLa cells were fractionated in mitochondria (left) or cytosolic (right) extracts and
analyzed by western blotting.mitochondria concentrations (Figure 3H). Conversely,
Shepherdin did not significantly depolarize normal mito-
chondria (see below, Figures 4A, 4C, 4E, and 4G), and
a scrambled peptidomimetic had no effect on tumor or
normal mitochondria (Figure 3H and see below, Figures
4A, 4C, 4E, and 4G). In addition, Shepherdin induced con-
centration-dependent release of cytochrome c from mito-
chondria isolated fromRaji lymphoblastoid cells (Figure 3I)
or a primary human sarcoma sample in vivo (Figure 3J),
whereas a scrambled peptidomimetic was ineffective
(Figures 3I and 3J). In contrast, 17-AAG did not induce260 Cell 131, 257–270, October 19, 2007 ª2007 Elsevier Inc.cytochrome c or Smac release from isolated tumor mito-
chondria (Figure 3K), and, only at high concentrations
(20 mM), it caused a small discharge of mitochondrial cyto-
chrome c, but not Smac, in the supernatant (Figure 3L).
Differential Regulation of Mitochondrial
Homeostasis in Tumor versus Normal Cell Types
Differently from tumor, i.e., Raji mitochondria (Figure 4A,
right), Shepherdin did not depolarize mitochondria iso-
lated from WS-1 normal human fibroblasts (Figure 4A,
left). To test whether this reflected a differential
Figure 3. Inhibition of Mitochondrial Hsp90 Induces Permeability Transition
(A–D) Intramitochondrial accumulation. FITC-conjugated Shepherdin (A–C) with (A and C) or without (B) Antennapedia cell-penetrating sequence or
cell-permeable scrambled peptidomimetic (D) was incubated in the presence (A, B, and D) or absence (C) of HeLa cell mitochondria and analyzed by
fluorescence microscopy.
(E) Quantification of intramitochondrial accumulation. Fluorescence intensity was quantified in isolated mitochondrial fractions. Mean ± SEM (n = 3).
(F) Submitochondrial fractions. HeLa cell mitochondria (white bars) incubated with FITC-conjugated Shepherdin without (Sheph) or with Antennape-
dia cell-penetrating sequence (Ant-Sheph) were fractionated in OM+IMS (gray bars) or IM+matrix (black bars) extracts and analyzed for fluorescence
intensity. None, untreated.
(G) Affinity chromatography. Raji mitochondrial extracts (MTE) were fractionated over Shepherdin-Sepharose (top) or scrambled peptidomimetic-
Sepharose (bottom) beads, and eluted fractions were analyzed by western blotting.
(H) Mitochondrial membrane potential. Increasing concentrations (mg) of TMRM-loaded HeLa cell mitochondria were incubated with Shepherdin and
analyzed for changes in fluorescence emission. A scrambled peptidomimetic was incubated with 60 mg of mitochondrial proteins. Arrow, point of
addition.
(I–J) Cytochrome c release. Mitochondria from Raji cells (I), or a human sarcoma sample (J), were treated with Shepherdin or scrambled peptidomi-
metic, and mitochondria (Mito) or supernatants (Sup) were analyzed by western blotting.
(K) Effect of 17-AAG. HeLa cell mitochondria were incubated with DMSO or 17-AAG and analyzed by western blotting.
(L) Release of intermitochondrial membrane proteins. Supernatants from 17-AAG-treated HeLa cell mitochondria in (K) were analyzed by western
blotting. MTE, mitochondrial extracts.Cell 131, 257–270, October 19, 2007 ª2007 Elsevier Inc. 261
Figure 4. Characterization of Mitochondrial Chaperones in Normal Cells
(A) Mitochondrial membrane potential. TMRM-loaded mitochondria from primary WS-1 fibroblasts (left) or Raji cells (right) were incubated with
Shepherdin or scrambled peptidomimetic and analyzed for changes in fluorescence emission.
(B) Glucose deprivation. WS-1 fibroblasts were incubated with (+) or without () glucose, and mitochondrial or cytosolic fractions were analyzed by
western blotting. HeLa cells were used as control.
(C) Mitochondrial membrane potential. TMRM-loaded mitochondria from glucose-starved WS-1 fibroblasts were incubated with Shepherdin or
scrambled peptidomimetic and analyzed for changes in fluorescence emission.
(D) Cytochrome c release. Mitochondria from normal mouse liver were incubated with Shepherdin or scrambled peptidomimetic and analyzed by
western blotting.
(E) Mitochondrial membrane potential in normal organs. TMRM-loadedmitochondria from normal mouse liver (left) or brain (right) were incubated with
Shepherdin or scrambled peptidomimetic and analyzed for changes in fluorescence emission.
(F) Role of oncogenic transformation. Wild-type NIH 3T3 or Ras-transformed NIH 3T3 fibroblasts were fractionated in mitochondria (MTE) or cytosolic
extracts and analyzed by western blotting.262 Cell 131, 257–270, October 19, 2007 ª2007 Elsevier Inc.
modulation of Hsp90 in normal cells, we ‘‘stressed’’ pri-
mary fibroblasts by glucose deprivation and checked
Hsp90 expression/function. Glucose deprivation of WS-
1 fibroblasts increased the levels of the endoplasmic retic-
ulumHsp90 homolog, Grp94, used as a control (Figure 4B,
left). In contrast, there were minimal changes in TRAP-1 or
Hsp90 expression in WS-1 mitochondria after glucose
deprivation (Figure 4B, right). Accordingly, Shepherdin or
scrambled peptidomimetic did not significantly depolarize
glucose-deprived WS-1 mitochondria (Figure 4C).
We next carried out experiments on mitochondria iso-
lated from primary tissues in vivo. Shepherdin induced cy-
tochrome c release from mitochondria isolated from
a p53/ mouse lymphoma specimen (Figure S2) but had
no effect on normal mouse liver mitochondria (Figure 4D).
In parallel, Shepherdin or scrambled peptidomimetic did
not depolarize mitochondria from normal mouse liver
(Figure 4E, left) or brain (Figure 4E, right). To checkwhether
this differential sensitivity was due to neoplastic transfor-
mation, we next used normal NIH 3T3 fibroblasts before
or after retroviral infection with a Ras mutant oncogene.
Normal NIH 3T3 fibroblasts exhibited low levels of mito-
chondrial Hsp90 (Figure 4F), andShepherdin did not signif-
icantly depolarize their mitochondria (Figure 4G, left). In
contrast, Ras-transformed NIH 3T3 fibroblasts exhibited
increased recruitment of Hsp90 to mitochondria, whereas
changes in TRAP-1 expression were less prominent
(Figure 4F), and cytosolic Hsp90 did not change before
or after Ras transformation (Figure 4F). Under these condi-
tions, Shepherdin readily depolarized mitochondria from
Ras-transformed NIH 3T3 fibroblasts (Figure 4G, right).
Regulation of TumorCell Survival byMitochondrial
Hsp90 Chaperones
Because of its ability to trigger mitochondrial dysfunction,
we next asked whether Shepherdin selectively killed tu-
mor cells. Fluorescein-conjugated Shepherdin accumu-
lated in the perinuclear area of tumor cells and colocalized
with the reactivity of a mitochondrial marker, MitoTracker
(Figure 5A). Although competent to accumulate inside iso-
lated mitochondria (Figures 3D and 3E), a cell-permeable
scrambled peptidomimetic did not colocalize with Mito-
Tracker in live cells (Figure 5B), thus potentially reflecting
nonspecific trapping in various cytosolic membranous
compartments in vivo. Accordingly, Shepherdin preferen-
tially accumulated in mitochondrial extracts of treated
cells, as compared with scrambled peptidomimetic,
whereas both sequences were comparably found in total
cell extracts or cytosol fractions (Figure 5C).
Within fiveminutes of addition, Shepherdin induced loss
of mitochondrial membrane potential in tumor cells
(Figure 5D) and discharge of mitochondrial cytochrome
c in the cytosol (data not shown). A cell-permeable scram-bled peptidomimetic was without effect (Figure 5D), and,
similarly, 17-AAG did not affect mitochondrial membrane
potential (Figure 5D) or cytochrome c release (Figure 5E)
in tumor cells. Within minutes, tumor cells exposed to
Shepherdin, but not scrambled peptidomimetic (Movies
S1 and S3), exhibited morphological features of apopto-
sis, including cell shrinkage, membrane blebbing (Movie
S2), and fusion/fission of mitochondria (Movie S4)
(Figure 5F). Consistent with this, a 1 hr exposure to Shep-
herdin was sufficient to kill disparate tumor cell types, but
not normal primary fibroblasts, in a concentration-depen-
dent manner (Figure 5G). In contrast, a scrambled pepti-
domimetic had no effect on normal or tumor cells
(Figure 5G). Under these conditions, 17-AAGdid not affect
tumor cell viability, and only a 24 hr treatment with the drug
resulted in partial cell killing (Figure 5H).
An Hsp90-Regulated Chaperone Network
in Mitochondria
Wenext looked formolecular interactions ofmitochondrial
Hsp90 chaperones that may regulate permeability transi-
tion in tumor cells. TRAP-1 immunoprecipitated from Raji
mitochondria was found in a complex with the immuno-
philin chaperone CypD (Figure 6A). Inhibition of the
peptidyl prolyl-cis, trans-isomerase activity of CypD with
cyclosporine A (CsA) prevented the formation of
a CypD-TRAP-1 complex in vivo (Figure 6A). In contrast,
inhibition of TRAP-1 ATPase activity with GA had no effect
(Figure 6A). Hsp90 immunoprecipitated from mitochon-
drial extracts also associated with CypD in vivo, and
CsA blocked this interaction (Figure 6B). In cell-free pull-
down experiments with recombinant proteins, TRAP-1
or Hsp90 directly and reciprocally bound to CypD, and
these reactions were abolished by CsA but not GA
(Figure S3). In contrast, GST was ineffective (Figure S3).
Finally, incubation of GST-CypD with Raji mitochondrial
extracts resulted in the isolation of both TRAP-1 and
Hsp90, and these interactions were inhibited by CsA,
but not GA (Figure 6C).
Molecular Requirements of Hsp90-Directed
Mitochondrial Homeostasis
We next carried out experiments to elucidate how Hsp90
chaperones regulate mitochondrial integrity. First, we
tested whether CypD contributed to cell death after tar-
geting of mitochondrial Hsp90 molecules. CsA inhibition
of CypD completely prevented depolarization of tumormi-
tochondria induced by Shepherdin (Figure 6D). Consistent
with the data above, Shepherdin had no effect on normal
liver mitochondria, with or without CsA (Figure S4). In ad-
dition, CsA significantly reversed Shepherdin-induced cell
death, preserving a 70% cell viability at concentrations of
the peptidomimetic (50 mM) that produce complete cell(G) Mitochondrial membrane potential in normal or transformed fibroblasts. TMRM-loaded mitochondria from NIH 3T3 (left) or Ras-transformed NIH
3T3 (right) fibroblasts were incubated with Shepherdin or scrambled peptidomimetic and analyzed for changes in fluorescence emission. For panels
(A), (C), (E), and (G), arrows indicate the points of addition.Cell 131, 257–270, October 19, 2007 ª2007 Elsevier Inc. 263
Figure 5. Differential Effects of Hsp90 Inhibitors on Mitochondrial Dysfunction and Tumor Cell Death
(A and B) Confocal microscopy. HeLa cells were double-labeled for mitochondria (MitoTracker) and FITC-conjugated Shepherdin (A) or cell-
permeable scrambled peptidomimetic (B) and analyzed by image merging.
(C) Quantification of subcellular accumulation. HeLa cells loaded with FITC-conjugated Shepherdin or scrambled peptidomimetic were fractionated
in total cell extracts (TCE), cytosolic extracts, or mitochondrial extracts (MTE) and analyzed for fluorescence intensity.
(D) Mitochondrial membrane potential. JC-1-loaded Raji cells treated with Shepherdin (solid line), 17-AAG (broken line), or scrambled peptidomimetic
(dotted line) were analyzed by flow cytometry. Mean ± SEM (n = 4).
(E) Cytochrome c release. Cytosolic extracts from 17-AAG-treated HeLa cells were analyzed by western blotting.
(F) Timelapse videomicroscopy. HeLa cells treated with Shepherdin or scrambled peptidomimetic were imaged for cellular morphology of apoptosis
(top) or mitochondria fusion/fission (bottom).
(G) Selectivity of Shepherdin-induced tumor cell killing. Tumor (left) or normal (right) cells were incubated with Shepherdin (solid lines) or scrambled
peptidomimetic (broken lines), and cell viability was quantified by MTT.
(H) Effect of 17-AAG on tumor cell killing. Tumor cells were incubated with 17-AAG for 4 hr (left) or 24 h (right) and analyzed for cell viability byMTT. For
(G) and (H), data are the mean of two independent experiments. The tumor cell types are HeLa (black), MCF-7 (brown), A431 (dark green), PC3 (light
green), H460 (blue), H1975 (purple), DU145 (blue green), HCT116 (light gray), MDA-MB-231 (dark gray), Raji (red), HL-60 (bright green), and U937
(yellow). The normal fibroblast cell types are WS-1 (black), HGF (red), and HFF (blue).264 Cell 131, 257–270, October 19, 2007 ª2007 Elsevier Inc.
Figure 6. A CypD-Chaperone Complex Regulates Tumor Cell Mitochondrial Permeability Transition
(A) TRAP-1 immunoprecipitation. Raji mitochondrial extracts treated with CsA or GA were immunoprecipitated with an antibody to TRAP-1 or IgG,
followed by western blotting.
(B) Hsp90 immunoprecipitation. Raji mitochondrial extracts treated with (+) or without () CsA were immunoprecipitated with an antibody to Hsp90 or
IgG, followed by western blotting.
(C) In vivo capture assay. GST or GST-CypD was incubated with Raji mitochondrial extracts with or without CsA or GA, followed by western blotting
and Coomassie staining.
(D) Mitochondrial membrane potential. TMRM-loaded HeLa cell mitochondria were treated with Shepherdin or scrambled peptidomimetic with
(broken lines) or without (solid lines) CsA. Data are from a representative experiment (n = 3). Arrow, point of addition.
(E) Effect of CsA on Shepherdin-induced tumor cell killing. HeLa cells treated with Shepherdin (solid symbols) or scrambled peptidomimetic (open
symbols) with (circles) or without (squares) CsA were analyzed by MTT. Mean ± SEM of triplicates of a representative experiment. **p = 0.0012-
0.0037; ***p < 0.0001.
(F) CypD knockdown. HeLa cells transfected with nontargeted (open symbols) or CypD-directed siRNA (solid symbols) were treated with Shepherdin
(squares) or scrambled peptidomimetic (circles) and analyzed by MTT. Mean ± SEM (n = 4). **p = 0.0074–.0099; *p = 0.029.
(G) TRAP-1 knockdown. HeLa cells were transfected with control nontargeted or TRAP-1-directed siRNA with or without CsA and analyzed by MTT.
Mean ± SEM of replicates of two independent experiments. ***p < 0.0001.
(H) Analysis of targeted cells. HeLa cells transfected with nontargeted (control) or CypD- (top) or TRAP-1-directed (bottom) siRNA were analyzed by
western blotting. None, nontransfected.
(I) TRAP-1 cytoprotection. Normal WS-1 fibroblasts were transfected with pcDNA3 or TRAP-1 cDNA, treated with staurosporine, and analyzed by
MTT. Mean ± SEM of three independent experiments. ***p < 0.0001.killing in untreated cultures (Figure 6E). To determine
whether the protective effect of CsA was specific, we
next acutely ablated its target, CypD, by small interfering
RNA (siRNA) and analyzed the effect of Shepherdin on
these cells. siRNA ablation of CypD effectively preventedShepherdin-induced tumor cell killing in a reaction quanti-
tatively similar to CsA (Figure 6F). In contrast, a scrambled
peptidomimetic had no effect on cell viability, with or
without CsA (Figure 6E), or in cultures transfected with
nontargeted or CypD-directed siRNA (Figure 6F).Cell 131, 257–270, October 19, 2007 ª2007 Elsevier Inc. 265
To determine which mitochondrial Hsp90 molecule an-
tagonized CypD, we next acutely ablated TRAP-1 expres-
sion, which is solely present in mitochondria, and studied
its effect on cell viability. TRAP-1 silencing reduced HeLa
cell viability by approximately 50%, as compared with
nontargeted siRNA, in a reaction completely reversed by
CsA (Figure 6G). In control experiments, TRAP-1- or
CypD-directed siRNA reduced the expression of their re-
spective target molecules, whereas nontargeted siRNA
had no effect (Figure 6H). As a corollary experiment, we
next transfected TRAP-1 in normal human fibroblasts,
which express very low levels of this protein (Figures 2F
and 2G), and tested their resistance to apoptosis. Expres-
sion of TRAP-1 inWS-1 (Figure 6I) or HFF (Figure S5) fibro-
blasts strongly counteracted apoptosis induced by vari-
ous concentrations of staurosporine, in agreement with
recent observations (Pridgeon et al., 2007), whereas con-
trol transfectants were ineffective.
Design and Chemical Synthesis
of Mitochondria-Directed GA
Although Shepherdin induced permeability transition and
triggered selective tumor cell death, 17-AAG had no effect
on mitochondrial integrity (Figures 3K and 3L) and ex-
hibited modest anticancer activity (Figure 5H). To recon-
cile these discrepancies between Hsp90 antagonists, we
hypothesized that 17-AAG was unable to accumulate in-
side mitochondria and thus inhibit mitochondrial Hsp90
chaperones. Accordingly, fluorescein-conjugated GA
failed to accumulate in isolated tumor cell mitochondria
(Figure S6A). To overcome this, we coupled by thioether
linkages a variant of 17-AAG, 17-(3-(4-Maleimidobutyr-
carboxamido)propylamino)-demethoxygeldanamycin (17-
GMB-APA-GA) (Figures S6B and S6C), to the Antenna-
pedia peptide (Ant), which delivers Shepherdin inside
mitochondria (Figure 3F). When conjugated to FITC, this
new compound, Ant-GA (Figures S6B and S6C), readily
accumulated inside isolated tumormitochondria, whereas
no signal was detected in the absence of mitochondria
(Figure S6A). Pretreatment with proteinase K abolished
the intramitochondrial accumulation of Ant-GA (Figure
S6A). In contrast, addition of proteinase K after Ant-GA in-
cubation with mitochondria was ineffective (Figure S6A),
indicating that the compoundwas protected from proteol-
ysis. Tumor cells exposed to Ant-GA exhibited degrada-
tion of Akt, an Hsp90 client protein (Figure S6D),
demonstrating that the new compound inhibited the
chaperone ATPase activity in vivo, indistinguishably from
the uncoupled mixture of Ant and GA (GA/Ant).
Induction ofMitochondrial Permeability Transition
and Selective Tumor Cell Death by Ant-GA
We next asked whether mitochondria-directed Ant-GA
recapitulated the effect of Shepherdin on mitochondrial
permeability transition and tumor cell killing. When added
to isolated tumor mitochondria, Ant-GA induced sudden
loss of mitochondrial membrane potential in a reaction
progressively attenuated at increasing mitochondria con-266 Cell 131, 257–270, October 19, 2007 ª2007 Elsevier Inc.centrations (Figure 7A). Similar to Shepherdin, CsA com-
pletely reversed Ant-GA-induced mitochondrial mem-
brane depolarization (Figure 7B), reinforcing a role of
CypD in this pathway. In addition, Ant-GA was selective
for tumor cells and triggered cytochrome c release from
isolated tumor mitochondria (Figure 7C, top) but did not
affect the membrane potential of normal brain mitochon-
dria, with or without CsA (Figure 7B), or the cytochrome
c content of normal liver mitochondria (Figure 7C, bottom).
Within the same time of exposure, the uncoupled mixture
of GA/Ant, or GA alone, had no significant effect on normal
or tumor mitochondrial membrane potential (Figure 7B) or
cytochrome c release (Figure 7C). Treatment with Ant-GA,
but not GA alone or the uncoupled Ant/GA mixture, re-
sulted in rapid (2 hr) and concentration-dependent tu-
mor cell killing (Figure 7D). In contrast, none of the com-
pounds decreased the viability of various normal human
fibroblasts (Figure 7E). Finally, tumor cell killing induced
by Ant-GA had the hallmarks of apoptosis with increased
caspase activity and was indistinguishable in tumor cells
either containing or lacking p53 (Figure 7F). In contrast,
the uncoupled mixture GA/Ant did not induce apoptosis
in p53+/+ or p53/ cells (Figure 7F).
DISCUSSION
In this study, we have shown that tumor cells organize
a mitochondrial chaperone network, which involves
Hsp90, its related molecule, TRAP-1, and the immunophi-
lin CypD. This complex maintains mitochondrial homeo-
stasis and antagonizes the function of CypD in perme-
ability transition. Conversely, inhibition of mitochondrial
Hsp90 chaperones with a novel class of mitochondria-di-
rected ATPase antagonists causes sudden loss of mito-
chondrial membrane potential, release of cytochrome c,
and massive death of tumor but not normal cells.
The identification of an Hsp90 chaperone network in mi-
tochondria fits well with an emerging paradigm that the
homeostatic functions of these molecules are orches-
trated in specialized subcellular microenvironments. This
relies on organelle-specific cofactors (Young et al., 2003)
and chaperones (Panaretou et al., 2002) but also on com-
partmentalized ATPase-directed ‘‘Hsp90-like’’ molecules,
including Grp94 in the endoplasmic reticulum (Loo et al.,
1998) and TRAP-1 in mitochondria (Cechetto and Gupta,
2000; Felts et al., 2000). Accordingly, an Hsp90 chaperone
network oversees protein folding quality control at the
endoplasmic reticulum (Young et al., 2001), trafficking of
signaling molecules at the plasma membrane (Garcia-
Cardena et al., 1998), delivery of preproteins to mitochon-
dria (Young et al., 2003), assembly and disassembly of
cytoskeletal proteins in the cytosol (Barral et al., 2002),
and disassembly of transcriptional complexes in the nu-
cleus (Freeman and Yamamoto, 2002). Although the exact
mechanism(s) of how Hsp90 chaperones are imported in
mitochondria remains to be fully elucidated, this may in-
volve the presence of a cleavable mitochondrial targeting
sequence in TRAP-1 (Felts et al., 2000) and potential
Figure 7. Ant-GA Induction of Mitochondrial Permeability Transition and Tumor Cell Death
(A) Mitochondrial membrane potential. Increasing concentrations (mg) of TMRM-loaded HeLa cell mitochondria were incubated with Ant-GA and
analyzed for changes in fluorescence emission. The uncoupled mixture GA/Ant was incubated with 60 mg of isolated mitochondria.
(B) Effect of CsA. TMRM-loaded HeLa cell (left) or mouse brain (right) mitochondria were incubated with the various compounds, with or without CsA,
and analyzed for changes in fluorescence emission. Data are from a representative experiment (n = 3). For (A) and (B), arrows indicate the points of
addition.
(C) Cytochrome c release. Mitochondria fromHeLa cells (top) or mouse liver (bottom) were incubated with Ant-GA or the uncoupledmixture of GA/Ant
and analyzed by western blotting.
(D) Tumor cell killing. HeLa cells were incubated with the various compounds and analyzed by MTT. Data are the means ± SEM of three independent
experiments.
(E) Effect on normal cells. Primary WS-1 (black), HGF (purple), or HFF (green) fibroblasts were treated with Ant-GA (solid squares) or the uncoupled
mixture of GA/Ant (open circles) and analyzed by MTT. Prostate cancer PC3 cells (blue) were used as control. Data are the means ± SEM of three
independent experiments.
(F) p53-independent induction of apoptosis. p53+/+ (top) or p53/ (bottom) HCT116 cells were treated with the various compounds and analyzed for
DEVDase activity and propidium iodide staining by flow cytometry. The percentage of cells in each quadrant is indicated.molecular interactions between Hsp90 and the mitochon-
drial import receptor, Tom70 (Young et al., 2003).
In mitochondria, Hsp90 chaperones establish a set of
CsA-sensitive molecular interactions with the matrix
immunophilin CypD and antagonize its ability to induce
mitochondrial permeability transition and cell death(Green and Kroemer, 2004). Because TRAP-1 knockdown
only partially removed this protective effect and induced
50% cell killing, it seems likely that both Hsp90 chaper-
ones are required to oppose CypD function and maintain
mitochondrial homeostasis, potentially via the assembly
of independent molecular complexes with CypDCell 131, 257–270, October 19, 2007 ª2007 Elsevier Inc. 267
(unpublished data). How CypD mediates mitochondrial
permeability transition has been the subject of intense in-
vestigation and may involve physical association with
pore components (Green and Kroemer, 2004), ANT-
independent mechanisms of pore formation (Kokoszka
et al., 2004), or remodeling of mitochondrial cristae for
full discharge of cytochrome c (Scorrano et al., 2002). Re-
gardless, genetic deletion of CypD (Baines et al., 2005;
Nakagawa et al., 2005) or inhibition of its peptidyl prolyl-
cis, trans-isomerase activity or molecular conformation
by CsA (Kokoszka et al., 2004) abolished mitochondrial
permeability transition, especially in response to oxidative
stress and Ca2+ overload, thus underscoring a critical role
in mitochondrial cell death.
The ability of mitochondrial Hsp90 chaperones to an-
tagonize the pore-forming properties of CypD and the re-
quirement of their ATPase activity in this process point to
a protective mechanism of protein folding/refolding. Al-
though this model applies well to a canonical view of the
permeability transition pore as a defined molecular entity
composed of ANT, VDAC, and CypD (Green and Kroemer,
2004), it is also readily, and perhaps even more applicable
to an alternative scenario, in which permeability transition
is mediated by clusters of misfolded proteins in stress-ex-
posed mitochondria (He and Lemasters, 2002). In this
case, mitochondrial Hsp90 chaperones would be ideally
positioned to bind the protein clusters, block pore con-
ductance via ATPase-directed protein refolding, and an-
tagonize the Ca2+-induced perturbation of CypD activity
potentially responsible for pore opening (He and Lemas-
ters, 2002). Conversely, inhibition of mitochondrial
Hsp90 ATPase activity eliminates this protective effect, re-
leasing CypD-mediated permeability transition and exe-
cution of mitochondrial cell death.
Importantly, this protective pathway by mitochondrial
Hsp90 chaperones appears almost exclusively opera-
tional in tumor cells, as opposed to most normal tissues.
This selectivity emphasizes how broadly Hsp90-directed
protein folding is exploited during oncogenic transforma-
tion and is ideally suited to preserve steady-state mito-
chondrial integrity, elevate the organelle threshold for
initiation of cell death (Green and Kroemer, 2004) during
cellular or environmental stress (Beere, 2004), and favor
drug resistance, which is a trait of Hsp90 in certain
model organisms (Cowen and Lindquist, 2005).
Conversely, the existence of ‘‘tumor-specific’’ qualitative
differences in mitochondrial protein composition and
molecular interactions (Mootha et al., 2003) may provide
new prospects for the development of selective antican-
cer agents.
We pursued this concept by designing a new class of
mitochondria-directed Hsp90 antagonists, aimed at dis-
abling this organelle-specific protective network. The pro-
totype molecule in this class was Shepherdin, which ex-
hibited marked rapidity of action, potent tumor cell
killing, and lack of toxicity for normal tissues in vivo (Ples-
cia et al., 2005). It is now clear that these properties reflect
the ability of Shepherdin to penetrate inside mitochondria,268 Cell 131, 257–270, October 19, 2007 ª2007 Elsevier Inc.bind mitochondrial TRAP-1 and Hsp90, and inhibit their
chaperone activity via an ATP competition mechanism
(Neckers and Ivy, 2003; Plescia et al., 2005), thus resulting
in CypD-mediated cell death. Although the ability of cell-
penetrating peptides, i.e., Antennapedia helix III, to target
cargos to mitochondria has been debated (Torchilin,
2006), this sequence is clearly required tomediate intrami-
tochondrial accumulation of Shepherdin, potentially via
electrostatic interactions with the negatively charged mi-
tochondrial matrix. Extending this paradigm, we synthe-
sized a mitochondria-directed variant of 17-AAG carrying
the Antennapedia peptide, i.e., Ant-GA. Differently from
unconjugated 17-AAG, which was not detected in mito-
chondria and had no effect on permeability transition,
Ant-GA efficiently accumulated inside mitochondria and
recapitulated the effect of Shepherdin with rapid induction
of mitochondrial cell death. The selectivity of these
agents, i.e., Shepherdin and Ant-GA, for tumor cells bodes
well for their potential clinical development as anticancer
agents and may reflect the near exclusive expression of
the Hsp90 network in tumor mitochondria, as well as the
higher affinity of tumor-associated Hsp90 for ATPase
pocket antagonists (Kamal et al., 2003). Accordingly,
Ant-GA or Shepherdin showed no toxicity for brain or liver
mitochondria, despite the presence of detectable Hsp90
and TRAP-1, respectively, in these organelles.
In summary, Hsp90-directed protein folding/refolding
functions as a novel regulatory mechanism of mitochon-
drial permeability transition (Green and Kroemer, 2004;
He and Lemasters, 2002). Although this pathway is selec-
tively exploited in tumor cells to elevate an antiapoptotic
threshold, the development of Hsp90 antagonists compe-
tent to accumulate in mitochondria may provide a new
class of potent and selective anticancer agents, poten-
tially devoid of side effects for normal tissues.
EXPERIMENTAL PROCEDURES
Mitochondria Isolation
Using a Mitochondria Isolation kit (Sigma-Aldrich), crude mitochondria
were isolated from mouse brain, liver, a primary lymphoma isolated
from a p53/ mouse, and a case of surgically resected human sar-
coma. Cultured cells were washed in TD buffer (135 mM NaCl, 5 mM
KCl, 25 mM Tris, pH 7.6), and cell pellets in CaRSB buffer (10 mM
NaCl, 1.5 mM CaCl2, 10 mM Tris, pH 7.5, and protease inhibitor)
were homogenized in a Dounce grinder and processed as described
(Dohi et al., 2004). Crude mitochondrial fractions were collected by
centrifugation at 60003 g for 10 min and suspended in MS buffer con-
taining 210 mM mannitol, 70 mM sucrose, 5 mM Tris, pH 7.6, 5 mM
EDTA, and protease inhibitors. In some experiments, samples were in-
cubated with FITC-conjugated Shepherdin for 10 min at 0C, layered
onto 1 M–1.5 M discontinuous sucrose gradient in 10 mM Tris, 5 mM
EDTA, pH 7.6, 2 mM DTT, plus protease inhibitors, and centrifuged
at 25,000 rpm in a Beckman SW41 rotor for 1 hr at 4C. The mitochon-
drial band between 1M and 1.5 M interface was collected and washed
in MS buffer. Protein concentrations were determined with a Protein
Assay reagent (BioRad) using BSA (Sigma-Aldrich) as standard. Pri-
mary WS-1 fibroblasts were cultured in high-glucose media (DMEM
containing 4.5 g/l glucose, Invitrogen) in the presence of 10% FBS
and antibiotics. Cells were washed, incubated in no-glucose DMEM
(Sigma) with sodium pyruvate and glutamine for 48 hr at 37C, and pro-
cessed for isolation of mitochondrial or cytosolic extracts.
Submitochondrial Fractionation
Submitochondrial fractionationwas performed by phosphate swelling-
shrinking as described before with minor modifications (Bijur and
Jope, 2003; Hovius et al., 1990). Briefly, purified mitochondrial pellets
isolated by sucrose step gradient were suspended in swelling buffer
(10 mM KH2PO4, pH 7.4, and protease inhibitor) and incubated for
20 min at 0C with gentle mixing. Mitochondria were mixed with equal
volume of shrinking buffer (10mMKH2PO4, pH 7.4, 32%sucrose, 30%
glycerol, 10 mMMgCl2, and protease inhibitor) for 20 min at 0
C. After
centrifugation at 10,0003 g for 10 min, the supernatant was collected
as containing outer membrane and intermembrane space fractions
(OM&IMS). Pellets were washed three times with 1:1 mixture of swell-
ing-shrinking buffer, suspended in swelling buffer, and sonicated to
disrupt the inner membrane, which was collected as containing inner
membrane and matrix fractions (IM&MA). OM&IMS and IM&MA were
further fractionated by centrifugation at 150,000 3 g for 1 hr at 4C.
The pellets were collected as OM and IM fractions, respectively. Su-
pernatants were concentrated using Centricon 10K and Microcon
10K centrifugal filters (Millipore) and collected as IMS and MA frac-
tions, respectively. Mitochondria isolated from HeLa cells or mouse
brain (2 mg/ml, 15 ml) were suspended in SHE buffer (250 mM sucrose
in HE buffer), diluted in 135 ml of SHE buffer or HE buffer (10 mM
HEPES, 1mMEDTA, pH 7.2), and incubated for 15min at 0Cwithme-
chanical disruption of the outer membrane by repeated pipetting. After
incubation with 50 mg/ml proteinase K (PK, Roche) for 10 min at 0C,
samples were mixed with 1 mM PMSF and centrifuged at 10,000 3
g for 10 min. Repartition of mitochondrial proteins from pellets to
supernatants in digitonin (0%–0.4%)-permeabilized mitochondria
was carried out as described (Dohi et al., 2004).
Mitochondrial Membrane Potential
Raji cells were treated with Shepherdin or control scrambled peptido-
mimetic (100 mM) or 17-AAG (5 mM), loaded with the mitochondrial
membrane potential-sensitive fluorescent dye JC-1, and analyzed
for changes in green/red fluorescence ratio by flow cytometry. Alterna-
tively, isolated mitochondria (100 mg) suspended in SB buffer were
incubated with 0.1 mM tetramethylrhodamine methyl ester (TMRM),
treated with Shepherdin or control scrambled peptidomimetic (0.5–
1.5 mM), 17-AAG (1.5 mM), or Ant-GA (1–1.5 mM), with or without CsA
(5 mM), and analyzed continuously at 549 nm excitation and 575 nm
emission (Photon Technology International, Inc). TMRM-loaded mito-
chondria in SBbuffer were allowed to reach stable fluorescence, which
was set as fully polarized state. The fluorescence intensity after treat-
ment with 2 mM CaCl2 was set as minimum membrane potential (fully
depolarized state). Changes in fluorescence intensity were plotted
as a ratio between maximum and minimum membrane potential. In-
creasing concentrations (10–100 mg) of TMRM-loaded mitochondria
isolated from HeLa or MCF-7 cells were diluted in 3 ml of SB buffer,
normalized to a total protein concentration of 500 mg with BSA, and
analyzed for changes in membrane potential in response to control
or various Hsp90 antagonists.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
six figures, and four movies and can be found with this article online
at http://www.cell.com/cgi/content/full/131/2/257/DC1/.
ACKNOWLEDGMENTS
We thank Drs. Bert Vogelstein for HCT116 cells, Steve Lyle for tissue
analysis, Roger Davis for normal and Ras-transformed NIH 3T3 fibro-
blasts, and Tracy Levin for electron microscopy. This work was sup-
ported by National Institutes of Health grants HL54131, CA90917,
and CA78810.Received: March 7, 2007
Revised: June 14, 2007
Accepted: August 3, 2007
Published: October 18, 2007
REFERENCES
Baines, C.P., Kaiser, R.A., Purcell, N.H., Blair, N.S., Osinska, H., Ham-
bleton, M.A., Brunskill, E.W., Sayen, M.R., Gottlieb, R.A., Dorn, G.W.,
et al. (2005). Loss of cyclophilin D reveals a critical role for mitochon-
drial permeability transition in cell death. Nature 434, 658–662.
Barral, J.M., Hutagalung, A.H., Brinker, A., Hartl, F.U., and Epstein,
H.F. (2002). Role of the myosin assembly protein UNC-45 as a molec-
ular chaperone for myosin. Science 295, 669–671.
Beere, H.M. (2004). ‘‘The stress of dying’’: the role of heat shock pro-
teins in the regulation of apoptosis. J. Cell Sci. 117, 2641–2651.
Bijur, G.N., and Jope, R.S. (2003). Rapid accumulation of Akt in mito-
chondria following phosphatidylinositol 3-kinase activation. J. Neuro-
chem. 87, 1427–1435.
Cechetto, J.D., and Gupta, R.S. (2000). Immunoelectron microscopy
provides evidence that tumor necrosis factor receptor-associated pro-
tein 1 (TRAP-1) is a mitochondrial protein which also localizes at spe-
cific extramitochondrial sites. Exp. Cell Res. 260, 30–39.
Chen, C.F., Chen, Y., Dai, K., Chen, P.L., Riley, D.J., and Lee, W.H.
(1996). A newmember of the hsp90 family of molecular chaperones in-
teracts with the retinoblastoma protein during mitosis and after heat
shock. Mol. Cell. Biol. 16, 4691–4699.
Collins, I., andWorkman, P. (2006). New approaches tomolecular can-
cer therapeutics. Nat. Chem. Biol. 2, 689–700.
Cowen, L.E., and Lindquist, S. (2005). Hsp90 potentiates the rapid
evolution of new traits: drug resistance in diverse fungi. Science 309,
2185–2189.
Dohi, T., Beltrami, E., Wall, N.R., Plescia, J., and Altieri, D.C. (2004).
Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis.
J. Clin. Invest. 114, 1117–1127.
Drysdale, M.J., Brough, P.A., Massey, A., Jensen, M.R., and Schoep-
fer, J. (2006). Targeting Hsp90 for the treatment of cancer. Curr. Opin.
Drug Discov. Dev. 9, 483–495.
Felts, S.J., Owen, B.A., Nguyen, P., Trepel, J., Donner, D.B., and Toft,
D.O. (2000). The hsp90-related protein TRAP1 is a mitochondrial pro-
tein with distinct functional properties. J. Biol. Chem. 275, 3305–3312.
Freeman, B.C., and Yamamoto, K.R. (2002). Disassembly of transcrip-
tional regulatory complexes by molecular chaperones. Science 296,
2232–2235.
Garcia-Cardena, G., Fan, R., Shah, V., Sorrentino, R., Cirino, G., Papa-
petropoulos, A., and Sessa, W.C. (1998). Dynamic activation of endo-
thelial nitric oxide synthase by Hsp90. Nature 392, 821–824.
Green, D.R., and Kroemer, G. (2004). The pathophysiology of mito-
chondrial cell death. Science 305, 626–629.
He, L., and Lemasters, J.J. (2002). Regulated and unregulated mito-
chondrial permeability transition pores: a new paradigm of pore struc-
ture and function? FEBS Lett. 512, 1–7.
Hovius, R., Lambrechts, H., Nicolay, K., and de Kruijff, B. (1990). Im-
proved methods to isolate and subfractionate rat liver mitochondria.
Lipid composition of the inner and outer membrane. Biochim. Biophys.
Acta 1021, 217–226.
Isaacs, J.S., Xu, W., and Neckers, L. (2003). Heat shock protein 90 as
a molecular target for cancer therapeutics. Cancer Cell 3, 213–217.
Johnstone, R.W., Ruefli, A.A., and Lowe, S.W. (2002). Apoptosis: a link
between cancer genetics and chemotherapy. Cell 108, 153–164.
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M.F., Fritz,
L.C., and Burrows, F.J. (2003). A high-affinity conformation of Hsp90
confers tumour selectivity on Hsp90 inhibitors. Nature 425, 407–410.Cell 131, 257–270, October 19, 2007 ª2007 Elsevier Inc. 269
Koga, F., Xu,W., Karpova, T.S., McNally, J.G., Baron, R., and Neckers,
L. (2006). Hsp90 inhibition transiently activates Src kinase and pro-
motes Src-dependent Akt and Erk activation. Proc. Natl. Acad. Sci.
USA 103, 11318–11322.
Kokoszka, J.E., Waymire, K.G., Levy, S.E., Sligh, J.E., Cai, J., Jones,
D.P., MacGregor, G.R., and Wallace, D.C. (2004). The ADP/ATP trans-
locator is not essential for the mitochondrial permeability transition
pore. Nature 427, 461–465.
Krauskopf, A., Eriksson, O., Craigen, W.J., Forte, M.A., and Bernardi,
P. (2006). Properties of the permeability transition in VDAC1(/) mi-
tochondria. Biochim. Biophys. Acta 1757, 590–595.
Loo,M.A., Jensen, T.J., Cui, L., Hou, Y., Chang, X.B., andRiordan, J.R.
(1998). Perturbation of Hsp90 interaction with nascent CFTR prevents
its maturation and accelerates its degradation by the proteasome.
EMBO J. 17, 6879–6887.
Mootha, V.K., Bunkenborg, J., Olsen, J.V., Hjerrild, M., Wisniewski,
J.R., Stahl, E., Bolouri, M.S., Ray, H.N., Sihag, S., Kamal, M., et al.
(2003). Integrated analysis of protein composition, tissue diversity,
and gene regulation in mouse mitochondria. Cell 115, 629–640.
Nakagawa, T., Shimizu, S., Watanabe, T., Yamaguchi, O., Otsu, K., Ya-
magata, H., Inohara, H., Kubo, T., and Tsujimoto, Y. (2005). Cyclophilin
D-dependent mitochondrial permeability transition regulates some ne-
crotic but not apoptotic cell death. Nature 434, 652–658.
Neckers, L., and Ivy, S.P. (2003). Heat shock protein 90. Curr. Opin.
Oncol. 15, 419–424.
Panaretou, B., Siligardi, G., Meyer, P., Maloney, A., Sullivan, J.K.,
Singh, S., Millson, S.H., Clarke, P.A., Naaby-Hansen, S., Stein, R.,
et al. (2002). Activation of the ATPase activity of hsp90 by the stress-
regulated cochaperone aha1. Mol. Cell 10, 1307–1318.
Pandey, P., Saleh, A., Nakazawa, A., Kumar, S., Srinivasula, S.M., Ku-
mar, V., Weichselbaum, R., Nalin, C., Alnemri, E.S., Kufe, D., and Khar-
banda, S. (2000). Negative regulation of cytochrome c-mediated olig-
omerization of Apaf-1 and activation of procaspase-9 by heat shock
protein 90. EMBO J. 19, 4310–4322.270 Cell 131, 257–270, October 19, 2007 ª2007 Elsevier Inc.Pearl, L.H., and Prodromou, C. (2006). Structure andmechanism of the
hsp90molecular chaperonemachinery. Annu. Rev. Biochem. 75, 271–
294.
Plescia, J., Salz, W., Xia, F., Pennati, M., Zaffaroni, N., Daidone, M.G.,
Meli, M., Dohi, T., Fortugno, P., Nefedova, Y., et al. (2005). Rational de-
sign of shepherdin, a novel anticancer agent. Cancer Cell 7, 457–468.
Price, J.T., Quinn, J.M., Sims, N.A., Vieusseux, J., Waldeck, K., Doch-
erty, S.E., Myers, D., Nakamura, A., Waltham, M.C., Gillespie, M.T.,
and Thompson, E.W. (2005). The heat shock protein 90 inhibitor, 17-al-
lylamino-17-demethoxygeldanamycin, enhances osteoclast formation
and potentiates bone metastasis of a human breast cancer cell line.
Cancer Res. 65, 4929–4938.
Pridgeon, J.W., Olzmann, J.A., Chin, L.S., and Li, L. (2007). PINK1 pro-
tects against oxidative stress by phosphorylating mitochondrial chap-
erone TRAP1. PLoS Biol. 5, e172. 10.1371/journal.pbio.0050172.
Sato, S., Fujita, N., and Tsuruo, T. (2000). Modulation of Akt kinase ac-
tivity by binding to Hsp90. Proc. Natl. Acad. Sci. USA 97, 10832–
10837.
Scorrano, L., Ashiya, M., Buttle, K., Weiler, S., Oakes, S.A., Mannella,
C.A., and Korsmeyer, S.J. (2002). A distinct pathway remodels mito-
chondrial cristae and mobilizes cytochrome c during apoptosis. Dev.
Cell 2, 55–67.
Torchilin, V.P. (2006). Recent approaches to intracellular delivery of
drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng. 8,
343–375.
Whitesell, L., and Lindquist, S.L. (2005). HSP90 and the chaperoning of
cancer. Nat. Rev. Cancer 5, 761–772.
Young, J.C., Moarefi, I., and Hartl, F.U. (2001). Hsp90: a specialized
but essential protein-folding tool. J. Cell Biol. 154, 267–273.
Young, J.C., Hoogenraad, N.J., and Hartl, F.U. (2003). Molecular chap-
erones Hsp90 and Hsp70 deliver preproteins to the mitochondrial im-
port receptor Tom70. Cell 112, 41–50.
Young, J.C., Agashe, V.R., Siegers, K., and Hartl, F.U. (2004). Path-
ways of chaperone-mediated protein folding in the cytosol. Nat. Rev.
Mol. Cell Biol. 5, 781–791.
